Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA’s $18.5 billion buyout offer because it undervalues the company.
Biotechnology company Genzyme Corp. said Monday it rejected Sanofi-Aventis SA’s $18.5 billion buyout offer because it undervalues the company.
France’s Sanofi-Aventis on Sunday publicly disclosed its $18.5 billion, $69-per-share cash offer for Genzyme Corp in a bid to rouse shareholders after failing to engage the U.S.
Biotechnology company Genzyme Corp.
Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company’s acceptance of two of his representatives to its board.
Activist investor Carl Icahn has abandoned his proxy fight at Genzyme Corp in return for the biotechnology company’s acceptance of two of his representatives to its board.
Biotechnology company Genzyme Corp.
Feb. 22 (Bloomberg) — Fluidigm Corp. , the biotechnology- equipment maker that had planned an initial public offering for this year, may postpone the share sale after 2010’s first IPOs stumbled, its chief executive officer said.
Genzyme Corp.
Biolexis is a premiere online resource for life sciences professionals, investors and entrepreneurs. The site offers personalized information biotechnology news and other biotechnology resources. Information is further organized by industry sector, therapeutic areas, technology focus, service orientation, and location. With Biolexis, you can: access over 5,000 biotechnology news strories and biotechnology articles. Search biotech company information, biotech news, biotech articles and biotech related press releases.